Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome

Detection of autoantibodies using chemiluminescence technologies

(2015) Michael Mahler et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk

(2015) V. Pengo et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2-Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti-Domain 1 to Anti-Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome

(2015) Laura Andreoli et al.   Arthritis & Rheumatology

Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome

(2014) R. Mondejar et al.   CLINICA CHIMICA ACTA

Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome

(2012) Savino Sciascia et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome

(2012) Michael Mahler et al.   AUTOIMMUNITY REVIEWS

Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies

(2012) M. Mahler et al.   CLINICA CHIMICA ACTA

What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?

(2012) Vittorio Pengo et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’)

(2011) Jose Luis Rodriguez-Garcia et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events

(2011) Kotaro Otomo et al.   ARTHRITIS AND RHEUMATISM

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study

(2011) V. Pengo et al.   BLOOD

The avidity of anti-β2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies

(2011) S Čučnik et al.   LUPUS

Pathogenesis of antiphospholipid syndrome: understanding the antibodies

(2011) Pier Luigi Meroni et al.   Nature Reviews Rheumatology

Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study

(2011) A. Ruffatti et al.   RHEUMATOLOGY

Antibodies to Domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)

(2011) A. Banzato et al.   THROMBOSIS RESEARCH

Anti- 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?

(2010) L. Andreoli et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I

(2010) Bas de Laat et al.   Current Rheumatology Reports

Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory

(2009) Xavier Bossuyt   AUTOIMMUNITY REVIEWS

Clinical significance of antiphosphatidylethanolamine antibodies in the so-called “seronegative antiphospholipid syndrome”

(2009) Marielle Sanmarco   AUTOIMMUNITY REVIEWS

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study

(2009) B. DE LAAT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS